

# Addressing systemic barriers, stigma for people living with viral hepatitis a

For all the work done to create access to healthcare, there are as many barriers which bring their own set of issues.

Some of these barriers are created by health services at an institutional or policy level, while others originate from stigmatising attitudes of staff within facilities. Still others come from health consumers themselves who have past experience of, or are influenced by, stories about discrimination in the health service. Each of these factors can reduce health outcomes, impede quality of life and ultimately result in adding to the cost of providing healthcare if health seeking behaviour is delayed. An exciting new initiative funded by the Commonwealth Department of Health is seeking to introduce system changes, particularly in relation to healthcare for people living with hepatitis B, hepatitis C and HIV. The project is run by the Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine (ASHM) and APNA is a valued partner.

The Australian Government and all jurisdictions have adopted national strategies<sup>1</sup> to help combat HIV, hepatitis B and hepatitis C. The suite of strategies also includes a *National Sexually Transmissible Infections Strategy*<sup>2</sup> and *National Aboriginal and Torres Strait Islander Blood-borne Viruses and Sexually Transmissible Infections Strategy*<sup>3</sup>.

Stigma and discrimination have been identified as leading causes for missed diagnoses of HIV and viral hepatitis, and for the failure of people living with these conditions to engage with the health system and seek timely care. This is one of a number of projects running over the next two years to facilitate the implementation of the national strategies.

APNA's involvement means APNA members will benefit from the outcomes of the project whilst giving APNA direct input into how the project is developed; Jane Henty is representing APNA on the Project Advisory Committee. A component of the Education

and Career Framework that APNA is currently developing will describe the expectations around what primary health care nurses can do in their role to limit the impact of stigma and discrimination and how they can address systems-level issues to improve access to care.

## An overview of HIV, HCV and HBV in health settings

Literature review and community consultations have been conducted to help inform the project. While the project focuses on the health system, it is commonly recognised that stigma in the community also impacts negatively on people's health seeking behaviour.

### HIV

HIV stigma has been fuelled from the first identification the acquired immune deficiency syndrome (AIDS)<sup>4</sup> and the initial terming of the condition Gay Related Immune Deficiency (GRID)<sup>5</sup> syndrome. This set the precondition for discrimination against a sub-population of the community, a subgroup which was already stigmatised, namely gay men. The Grim Reaper campaign was designed to shock the community and prime them to heed public health promotion education and information. Fear permeated the health system, schools<sup>6</sup> and other services, and we still experience the consequences of this in residual discriminatory practices and fear by people living with HIV that disclosure will result in discrimination or exclusion in some form. This largely came about because it was easy to attribute HIV to a sub-population rather than to a virus and specific practices which would facilitate its transmission. Globally more women than men are living with HIV<sup>7</sup> and while infection patterns differ around the globe, HIV is transmitted by risk behaviours, not risk groups.

Attempts to protect people living with HIV from discrimination have resulted in processes and systems in some jurisdictions which keep HIV off the health record or which require data about HIV to be coded.

### Hepatitis C

A similar chain of events has occurred in hepatitis C which is readily transmitted through contaminated injecting or surgical equipment and contaminated blood and blood products. Recreational injection drug use, where injecting equipment is shared with a person living with hepatitis C is a common route of infection. Hepatitis C can also be transmitted sexually, particularly where there is the potential for blood to blood transmission, and through other skin penetration procedures such as tattooing with contaminated equipment. While periods of injection drug use may be sporadic or short lived, chronic hepatitis C infection is lifelong unless treated. The stigma associated with current or past drug use makes it difficult for many people to come forward for testing. Once in the health system, people who are viewed as drug-users can experience suboptimal treatment, or be viewed as untrustworthy or even criminal.

There is considerable evidence that people who inject drugs can comply with dosing treatment schedules and this is evidenced through compliance with methadone<sup>8</sup> and other opiate substitution programs,<sup>8</sup> and a number of drug trials among people who are injection drug users.<sup>9</sup> A strong public health argument in favour of treating injection drug users is to reduce the amount of circulating HCV in the community.<sup>10</sup>

### Hepatitis B

Hepatitis B is endemic in a number of regions and communities worldwide,<sup>11</sup> including in the Australian Indigenous population which can be identified back many thousands of years,<sup>12</sup> and in many Asian countries with significant migration to Australia such as Vietnam. Vaccination is the most effective way to reduce chronic HBV, but that impact is not realised until subsequent generations. In Australia it is estimated that 240,000 people have chronic HBV, but while it is increasing only 50% of these have been diagnosed.<sup>13</sup> Many people who have been diagnosed are not in



# and discrimination and HIV



**Levinia Crooks**

CEO, Australasian Society for HIV Viral Hepatitis and Sexual Health Medicine  
La Trobe University  
University of New South Wales



care and it is thought that a number of competing factors are responsible for this. For example new migrants and refugees often have competing demands on health and are dealing with adjustment to a new country. It is thought that poor uptake of health services may be a result of previous negative experience in seeking healthcare and/or fear of disclosure. Progressive HBV disease is largely asymptomatic, and significant liver damage, including liver cancer can result, leading to death or highly costly procedures such as liver transplant. Structural facilitators as well as the removal of discriminatory practices and redressing concerns around disclosure are required.

## With so many priorities why is this important?

As nurses you manage competing demands. Inviting more people into an often overcrowded health service can sound counterintuitive. But projects such as this one are aimed ultimately at reducing the health system burden: getting people tested early allows timely treatment

initiation and averts new infections; task shifting, particularly to the community at earlier stages of disease progression, can avert more costly tertiary care as well as improve quality of life in people living with a chronic condition.

Systems-based approaches to prevention, testing, diagnosis, monitoring and treatment can reduce reliance on outmoded assumptions about infection demographics. We are all committed to delivering high quality services, and this can only be done if those services are delivered free from stigma and discrimination. Stigma and discrimination is not a one off concern, nor is it restricted only to the conditions covered by this project. We hope that by focusing on principles, as well as exploring specific initiatives, over the next two years we will, with APNA, be able to develop durable resources to assist nurses respond to these issues within our services. We see this as being important for new and emerging health service managers and those in training, as well as for those of us with established careers.

## What will we actually see come from this project?

We aim to develop a number of online learning modules that will assist nurses to identify areas of concern in their services. We will also make available online tools, checklists and resources to help nurses put in place workplace strategies, policies and procedures.

The project is also working with the Royal Australian College of General Practitioners (RACGP) to develop training and resources. APNA will look at providing opportunities for primary health care nurses to discuss the issues raised in the review and to think critically about what steps should be taken. This may involve challenging some established opinions about health service access.

In early 2017 the Australian Healthcare and Hospitals Association (AHHA) will conduct a simulation for the project, bringing together a range of health service partners, collaborators, implementers and consumers to finalise a program of activity for the project through 2017–2018.

ASHM is committed to being transparent. Project resources and processes will be made available on the ASHM project website as well as key resources being made available through the APNA website. We also hope to see presentations submitted for the APNA conference and through presentations at other APNA forums and webinars.

Any enquiries about this work can be directed to [SandDProject@ashm.org.au](mailto:SandDProject@ashm.org.au).



# Addressing systemic barriers, stigma and discrimination for people living with viral hepatitis and HIV

## References

1. Australian Government Second National Hepatitis B Strategy, Fourth National Hepatitis C Strategy and Seventh National HIV Strategy. <http://www.health.gov.au/internet/main/publishing.nsf/Content/ohp-bbvs-1>
2. Australian Government Third National Sexually Transmissible Infections Strategy <http://www.health.gov.au/internet/main/publishing.nsf/Content/ohp-bbvs-1>
3. Australian Government Fourth National Aboriginal and Torres Strait Islander Blood Borne Viruses and STI Strategy <http://www.health.gov.au/internet/main/publishing.nsf/Content/ohp-bbvs-1>
4. MMWR Epidemiologic Notes and Reports Pneumocystis Pneumonia --- Los Angeles June 5, 1981 / 30(21):1-3 [http://www.cdc.gov/mmwr/preview/mmwrhtml/june\\_5.htm](http://www.cdc.gov/mmwr/preview/mmwrhtml/june_5.htm)
5. MMWR A Cluster of Kaposi's Sarcoma and Pneumocystis carinii Pneumonia among Homosexual Male Residents of Los Angeles and Orange Counties, California June 18, 1982 / 31(23):305-7 <http://www.cdc.gov/mmwr/preview/mmwrhtml/00001114.htm>
6. Associated Press Eve Van Grafhorst <http://www.apnewsarchive.com/1985/Three-Year-Old-AIDS-Girl-Banned-From-School-After-Biting-Friend/id-ff0d3f616d98ca813e095071fd83b7f9>
7. amfAR (2015) Statistics for Women with HIV <http://www.amfar.org/about-hiv-and-aids/facts-and-stats/statistics--women-and-hiv-aids/>
8. RP Mattick, C Breen, J Kimber (2009) Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence - Cochrane database2009. <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD002209.pub2/pdf/>
9. Backmund M, Meyer K, Von Zietel M, Eichenlaub D. Treatment of hepatitis C infection in injection drug users. *Hepatology*. 2001 Jul; 34(1):188-93. <http://www.ncbi.nlm.nih.gov/pubmed/11431750>
10. Grebely J and Dore GJ. Can hepatitis C virus infection be eradicated in people who inject drugs? *Antiviral Research* 2014; 104(1): 62-72
11. J.J. Ott, G.A. Stevens, J. Groeger & S.T. Wiersma (2012) Global epidemiology of hepatitis B virus infection: New estimates of age-specific HBsAg seroprevalence and endemicity. <http://dx.doi.org/10.1016/j.vaccine.2011.12.116>
12. Sugauchi, F., Mizokami, M., Orito, E., Ohno, T., Kato, H., Suzuki, S., Kimura, Y., Ueda, R., Butterworth, L. A. and Cooksley, W. G. E. (2001) A novel variant genotype C of hepatitis B virus identified in isolates from Australian Aborigines: complete genome sequence and phylogenetic relatedness. *Journal of General Virology*, 82 4: 883-892.
13. McLachlan, J., & Cowie B. Hepatitis B Mapping Project: Estimates of chronic hepatitis B diagnosis, monitoring and treatment by Medicare Local. ASHM <http://www.ashm.org.au/resources/Pages/1976963416.aspx>

## PROTECTION FOR ADULTS TOO



**Prevenar 13**  
Pneumococcal polysaccharide conjugate vaccine, 13-valent adsorbed

PBS Information: This product is listed on the National Immunisation Programme (NIP) for children only and is not listed on the PBS. Refer to the NIP Schedule.

Please review full Product Information before prescribing. Product Information is available on request on 1800 675 229 or at [www.pfizer.com.au](http://www.pfizer.com.au)

**Indications:** Active immunisation for the prevention of disease caused by *Streptococcus pneumoniae* serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F in adults and children from 6 weeks of age. **Dose:** 0.5 mL IM. **Infants 6 weeks to 6 months of age:** 3 doses at least one month apart. A single booster should be given in the second year, at least 2 months after the primary series. **Previously unvaccinated children:** Varies with age at first dose, see full PI. **Children previously vaccinated with Prevenar (7vPCV):** Children 12 months to 5 years who have completed primary infant immunisation with 7vPCV and children 6 to 17 years who have received one or more doses of 7vPCV may receive 1 dose, at least 8 weeks after the final dose of 7vPCV. **Adults:** 1 dose. **Special Populations (higher risk, e.g. HIV, SCD):** 1 dose. HSOT: 4 doses. If sequential administration of Prevenar 13 and 23vPPV is considered, give Prevenar 13 first. **Contraindications:** Hypersensitivity to any component of the vaccine, including diphtheria toxoid. Allergic or anaphylactic reaction following prior administration of 7vPCV. **Precautions:** Do not administer intravenously, intravascularly, intradermally or subcutaneously. Avoid injecting into or near nerves or blood vessels. Do not inject into gluteal area. Postpone administration in acute, moderate or severe febrile illness. Only protects against *Streptococcus pneumoniae* serotypes included in the vaccine and may not protect all individuals from pneumococcal disease. Consider the risks of IM injection in infants or children with thrombocytopenia or any coagulation disorder. Appropriate treatment and supervision must be readily available in case of a rare anaphylactic event. Prophylactic antipyretic medication is recommended for children receiving concomitant whole-cell pertussis vaccines, and for children with seizure disorders or history of febrile seizures. Consider the potential risk of apnoea when administering to very premature infants. **Very Common/Common Adverse Effects:** **Children 6 weeks to 5 years:** Injection site reactions (redness, pain, swelling), fever, diarrhoea, vomiting, decreased appetite, drowsiness/increased sleep, restless sleep/decreased sleep, rash, irritability. **Children and adolescents 5 to 17 years:** Irritability, Injection site reactions (redness, pain, swelling), somnolence, poor quality sleep, injection site tenderness (including impaired movement), fever, decreased appetite, vomiting, diarrhoea, headaches, rash. **Adults:** Diarrhoea, vomiting, nausea, chills, fatigue, injection site reactions (redness, pain, swelling), limitation of arm movement, fever, new or aggravated joint or muscle pain, decreased appetite, headaches, rash. **Adults >65 years** reported fewer adverse effects than younger adults. Adverse effects were generally most common in young adults 18 to 29 years. See full PI for details (V10516). **References:** 1. PREVENAR 13® Approved Product Information. ©Registered trademark. Pfizer Australia Pty Limited, 38-42 Wharf Road, West Ryde, NSW 2114. PP-PNA-AUS-0060. PFA2275HP/AP-F. 11/16 GHG